



## (51) International Patent Classification:

*A61K 31/395* (2006.01) *A61K 31/4353* (2006.01)  
*A61K 31/403* (2006.01) *A61K 31/33* (2006.01)

## (21) International Application Number:

PCT/US2023/078978

## (22) International Filing Date:

07 November 2023 (07.11.2023)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:


63/423,351 07 November 2022 (07.11.2022) US

## (71) Applicant: HUMANWELL PHARMACEUTICAL US, INC. [US/US]; 421 Sovereign Court, Ballwin, Missouri 63011 (US).

## (72) Inventors: ZHAO, Shuo; c/o Humanwell Pharmaceutical US, Inc., 421 Sovereign Court, Ballwin, Missouri 63011

(US). LIAO, Subo; c/o Humanwell Pharmaceutical US, Inc., 421 Sovereign Court, Ballwin, Missouri 63011 (US). LI, Ming; c/o Humanwell Pharmaceutical US, Inc., 421 Sovereign Court, Ballwin, Missouri 63011 (US). YANG, Jun; c/o Humanwell Pharmaceutical US, Inc., 421 Sovereign Court, Ballwin, Missouri 63011 (US). ZHOU, Hao; c/o Humanwell Pharmaceutical US, Inc., 421 Sovereign Court, Ballwin, Missouri 63011 (US). DING, Zejian; c/o Humanwell Pharmaceutical US, Inc., 421 Sovereign Court, Ballwin, Missouri 63011 (US). ZHENG, Xin; c/o Humanwell Pharmaceutical US, Inc., 421 Sovereign Court, Ballwin, Missouri 63011 (US). NING, Youjian; c/o Humanwell Pharmaceutical US, Inc., 421 Sovereign Court, Ballwin, Missouri 63011 (US). LIANG, Dali; c/o Humanwell Pharmaceutical US, Inc., 421 Sovereign Court, Ballwin, Missouri 63011 (US). LIU, Rong; c/o Humanwell Pharmaceutical US, Inc., 421 Sovereign Court, Ballwin, Missouri 63011 (US). LIU, Zewen; c/o Humanwell Pharmaceutical

## (54) Title: SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS AND THEIR APPLICATIONS

**FIG. 1A**

(57) **Abstract:** The invention discloses a nitrogen-containing heterocyclic derivative of a somatostatin receptor subtype 4 (SSTR4) small molecule agonist and its pharmaceutical composition, preparation method, and use. The nitrogen-containing heterocyclic derivative of the SSTR4 small molecule agonist is represented by formula (I), and the specific substituents and definitions are as described in the specification. The nitrogen-containing heterocyclic derivatives of SSTR4 small molecule agonists exhibit good binding and agonistic activities with SSTR4. Such compounds or their pharmaceutical compositions have great potential in treating and/or preventing pain disorders related to SSTR4 receptor.



US, Inc., 421 Sovereign Court, Ballwin, Missouri 63011 (US).

(74) **Agent: DOTY, Kathryn J.** et al.; POLSINELLI PC, PO Box 140310, Kansas City, Missouri 64114-0310 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) **Date of publication of the international search report:**

27 June 2024 (27.06.2024)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 23/78978

## A. CLASSIFICATION OF SUBJECT MATTER

IPC - INV. A61K 31/395, A61K 31/403, A61K 31/4353 (2024.01)  
ADD. A61K 31/33 (2024.01)

CPC - INV. A61K 31/395, A61K 31/403, A61K 31/4353

ADD. A61K 31/33

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	← CN 112778274 A (Sichuan Haisco Pharmaceutical Co. Ltd.), 11 May 2021 (11.05.2021), entire document, especially page 12, para 4; page 17, compound 1E	1-2, 6-7, 12
Y	← "Pubchem CID 3868064", Create date: 12 September 2005 (12.09.2005), entire document, especially page 2, compound listed	1-2, 6-7, 12
A	← "Pubchem CID 156703878", Create date: 10 November 2021 (10.11.2021), entire document, especially page 2, compound listed	1-2, 6-7, 12
A	WO 2020/243415 A2 (Ikena Oncology, Inc.), 03 December 2020 (03.12.2020), entire document, especially para[0005], [0010], [0014]	1-2, 6-7, 12
A	WO 2012/149540 A1 (Holson et al.), 01 November 2012 (01.11.2012), entire document, especially page 2, ln 25-30; page 13, ln 12-30; pages 14-15	1-2, 6-7, 12
A	WO 2019/224773 A1 (Glaxosmithkline Intellectual Property Development Limited), 28 November 2019 (28.11.2019), entire document, especially page 3, ln 10-30; page 4, ln 1-21	1-2, 6-7, 12



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"D" document cited by the applicant in the international application	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"E" earlier application or patent but published on or after the international filing date	"&" document member of the same patent family
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 01 February 2024	Date of mailing of the international search report <b>APR 17 2024</b>
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-8300	Authorized officer Kari Rodriguez Telephone No. PCT Helpdesk: 571-272-4300

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 23/78978

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:  
---see supplemental box---

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-2, 6-7, 12

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 23/78978

## Box III: lack of unity

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I+: Claims 1-12 are directed to a compound having a structure of Formula (I) as seen in instant claim 1. Claim 1 will be searched to the extent that it encompasses the first species of claim 1, represented by a compound of Formula (I), or stereoisomer, pharmaceutically acceptable salt, solvate, deuterate, metabolite, or prodrug thereof, wherein R1 and R2 are independently H; A is selected from the first structure listed in instant claim 1 wherein  $n = 1$  and  $m = 1$ ; R3 is H; B is selected from an aromatic ring wherein the aromatic ring is phenyl as listed in instant claim 7. It is believed that claims 1-2, 6-7, and 12 read on this first named invention, and thus these claims will be searched without fee. This first named invention has been selected based on the guidance set forth in section 10.54 of the PCT International Search and Preliminary Examination Guidelines. Applicant is invited to elect additional compounds of claim 1, wherein each additional compound elected will require one additional invention fee. Applicants must specify the claims that encompass any additionally elected compound. Applicants must further indicate, if applicable, the claims which encompass the first named invention, if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the '+' group(s) will result in only the first claimed invention to be searched. Additionally, an exemplary election wherein different actual variables are selected is suggested. An exemplary election would be a compound of Formula, or stereoisomer, pharmaceutically acceptable salt, solvate, deuterate, metabolite, or prodrug thereof, wherein R1 is deuterium; R2 is H; A is selected from the first structure listed in instant claim 1 wherein  $n = 1$  and  $m = 1$ ; R3 is H; B is selected from an aromatic ring wherein the aromatic ring is phenyl as listed in instant claim 7 (i.e., claims 1-2, 6-7, 12).

Group II: Claims 13-17 are directed to a method of treating and/or preventing a SSTR4 receptor-related disease or disorder, the method comprising administering a pharmaceutically effective amount of the pharmaceutical composition of claim 12.

The group of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

## Special Technical Features:

Each invention in Group I+ includes the technical feature of a unique compound of Formula (I), which is not required by any other invention of Group I+.

Group II requires a method of treating and/or preventing a SSTR4 receptor-related disease or disorder, the method comprising administering a pharmaceutically effective amount of the pharmaceutical composition of claim 12, which is not required for Group I+.

## Common Technical Features:

The inventions of Groups I+ and II share the technical feature of a compound of Formula (I).

These shared technical features, however, do not provide a contribution over the prior art as being anticipated by a document entitled "Pubchem CID 156703878" (hereinafter 'Pubchem-878'). Pubchem-878 teaches a compound of Formula (I), or stereoisomer, pharmaceutically acceptable salt, solvate, deuterate, metabolite, or prodrug thereof; wherein R1 and R2 are independently H; A is selected from the first structure listed in instant claim 1 wherein  $n = 1$  and  $m = 1$ ; R3 is H; B is selected from an aromatic ring (see page 2, compound listed).

As said compound was known in the art, these cannot be considered special technical features that would otherwise unify the inventions of Groups I+ and II. The inventions of Group I+ and II thus lack unity under PCT Rule 13.